The Decline Theory in neurology states that the pathophysiology of neurological diseases results in an overall decrease in brain activity. It is an alternative to the Excitotoxicity Theory, which suggests that increased neuron activity is a primary cause of neurodegenerative diseases. The Decline Theory suggests that the decrease in brain activity is due to decreased synaptic communication between neurons and a decreased release of neurotransmitters. There are three main components of the Decline Theory. First, neuronal networks and connections become weakened as the interactions between neurons slow down. This results in less information being exchanged between neurons leading to a decrease in brain activity. Secondly, decreased release of neurotransmitters can occur due to a decrease in neurotransmitter production, or because of neuronal dysfunction. Finally, the degeneration of axons can lead to disruption and damage to neural networks resulting in a decrease of brain activity. The Decline Theory has been proposed in neurological diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. It is often suggested to be a more comprehensive explanation for the pathogenesis of these diseases than the Excitotoxicity Theory, as it takes into account both the decreased activity of neurons and the decline in the networks that these neurons are connected to. In addition, the Decline Theory suggests that therapies for neurological diseases should focus on both restoring the function of existing neurons and connecting them effectively, as well as forming new, strong neuronal networks. This differs from the Excitotoxicity Theory, which suggests therapies should focus solely on restoring excitatory activity. A better understanding of the molecular pathways and mechanisms of the Decline Theory could lead to improved treatments and interventions for neurological diseases.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States